Female patients, if of childbearing potential, must have a negative serum pregnancy test within  hours prior to the date of the first dose of study medication.
Women of childbearing potential must have a negative serum or urine pregnancy test within  hours prior to start of study drug.
For women of childbearing potential (defined as women with menses within the past  years), a negative serum pregnancy test must be documented prior to registration; NOTE: in addition to screening, serum pregnancy test must be performed on females of childbearing potential within  hours before the start of investigational product; when possible, these tests can be one-in-the-same (if screening pregnancy test was performed within  hours of first ponatinib dose, no need to repeat)
Women of childbearing potential must have negative pregnancy test within  hours of enrollment
Female participants of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study drug
Patient (of childbearing potential) is not breastfeeding, has a negative serum pregnancy test within  hours prior to taking study drug, and agrees to abstain from activities that could result in pregnancy from Screening through  days after the last dose of study drug, or is of nonchildbearing potential.
Female participants of childbearing potential must have a negative serum pregnancy test within  hours prior to receiving the first dose of study therapy
Women of childbearing potential must:\r\n* Have a negative serum or urine pregnancy test within  hours prior to the start of study therapy\r\n* Agree to utilize an adequate method of contraception throughout treatment and for at least  weeks after study therapy is completed\r\n* Be advised of the importance of avoiding pregnancy during trial participation and the potential risks of an unintentional pregnancy
Women must not be pregnant or breastfeeding; females of childbearing potential should have  negative pregnancy tests (sensitivity of at least  mIU/mL); the first test should be performed within - days, and the second test within  hours prior to prescribing lenalidomide
Female subject of childbearing potential should have a negative serum pregnancy within  hours prior to receiving the first dose of study medication.
Negative serum or urine pregnancy test for women within  hours of receiving the first dose of the study medication for women of childbearing potential.
Women of childbearing potential must have a negative pregnancy test within  hours prior to receiving the first dose of study medication
Pregnant or nursing women. \r\n* NOTE: Women of reproductive potential must have a negative serum pregnancy test performed within  hours of starting conditioning chemotherapy
Female participants of childbearing potential must have a negative serum pregnancy within  hours prior to enrollment
Women of childbearing potential must have a negative serum pregnancy test at screening and =<  hours prior to day  of study treatment
Women of childbearing potential must have a negative serum or urine pregnancy test within  hours prior to the start of nivolumab.
Pregnant or nursing women; NOTE: Women of reproductive potential must have a negative serum pregnancy test performed within  hours of starting conditioning chemotherapy
Female participants of childbearing potential should have a negative serum pregnancy test within  hours prior to receiving first dose of trial medication.
Female subject of childbearing potential should have a negative serum pregnancy within  hours prior to receiving the first dose of study medication
have a negative urine pregnancy test within  hours prior to the first dose of study treatment, and
Women of childbearing potential must have a negative serum or urine pregnancy test within  hours prior to the first dose of pembrolizumab
For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than  mIU/m within  hours before the start of study medication
Female subject of childbearing potential should have a negative serum pregnancy testing at screening visit and within  hours prior to the first dose of study medication
Female subject of childbearing potential should have a negative serum pregnancy within  hours prior to receiving the first dose of study medication
Negative serum pregnancy test for women of childbearing potential =<  days prior to registration; Note: a second pregnancy test may be required =<  hours prior to receiving the first dose of study medication
Women of childbearing potential also may not be breast feeding and must have a negative serum or urine pregnancy test within  hours before the start of study treatment
A female who is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional  hours (Period ) or  hours (Period ), respectively, after the last dose of blinatumomab (Female subjects of childbearing potential should only be included in the study after a confirmed menstrual period and a negative highly sensitive urine or serum pregnancy test).
Women of childbearing potential must have a negative serum or urine pregnancy test within  hours prior to the start of nivolumab
Women of childbearing potential must have a negative serum or urine pregnancy test within  hours prior to start of IRX
Negative serum pregnancy test within  hours before starting study treatment in women with childbearing potential
Women of childbearing potential (defined as having a menstrual cycle within the past  months and not having had a surgical procedure to accomplish sterilization) must have a negative serum pregnancy test within seven days of screening and within  hours prior to the start of each nivolumab dose
Negative serum or urine pregnancy test for women within  hours of receiving the first dose of the study medication for women of childbearing potential
Women of childbearing potential (WOCBP) must have negative pregnancy test within  hours prior to day (D) of treatment
Negative serum or urine pregnancy test for women within  hours of receiving the first dose of the study medication for women of childbearing potential
Women of childbearing potential must:\r\n* Have a negative serum or urine pregnancy test within  hours prior to the start of study therapy\r\n* Agree to utilize an adequate method of contraception throughout treatment and for at least  weeks after study therapy is completed\r\n* Be advised of the importance of avoiding pregnancy during trial participation and the potential risks of an unintentional pregnancy
For women of childbearing potential only: Negative pregnancy test =< - days prior to registration; NOTE: the patient must have an additional negative pregnancy test =<  hours prior to receiving the initial prescription of lenalidomide, per requirements of the REVLIMID Risk Evaluation and Mitigation Strategies (REMS) program
Female subject's of childbearing potential must have a negative serum pregnancy test within  hours prior to receiving the first dose of study medication
Negative serum or urine pregnancy test within  hours of commencement of treatment in premenopausal women
Negative serum pregnancy test with  hours prior to start of study drug
Negative serum pregnancy test within  hours prior to the first study dose in all women of childbearing potential
Negative serum or urine pregnancy test within  hours prior to registration for women of childbearing potential
If subject is a female of childbearing potential (FCBP), she must have a negative serum or urine pregnancy test with a sensitivity of at least  mIU/mL within  -  days prior to and again within  hours of prescribing lenalidomide
Negative serum pregnancy test within  hours before starting study treatment in women with childbearing potential
Pregnancy or lactation at the time of randomization or intention to become pregnant during the study; (Note: Pregnancy testing according to institutional standards for women of childbearing potential must be performed within  hours prior to randomization)
Female subjects of childbearing potential should have a negative serum pregnancy test within  hours of starting first dose of study drug.
Women who are pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within  hours prior to the start of nivolumab.
Negative (serum or urine) pregnancy test done =<  days prior to registration, for women of childbearing potential only; NOTE: a second pregnancy test must be performed within  hours prior to the start of lenalidomide; the subject may not receive lenalidomide until the study doctor has verified that the results of these pregnancy tests are negative
Negative serum pregnancy test within  hours before starting study treatment in women with childbearing potential
For women of childbearing potential, a serum pregnancy test within  hours prior to registration
Negative serum pregnancy test within  hours before starting study treatment in women with childbearing potential
Patients of childbearing potential must have negative pregnancy serum test within  hours of being dosed
Female participants of childbearing potential must have  negative urine pregnancy tests (with a sensitivity of at least  Milli-international units/Milliliter) within  to  days and within  hours prior to receiving study medication.
Female patient, if of childbearing potential, has a negative serum pregnancy test within  hours of taking study medication and agrees to abstain from activities that could result in pregnancy from enrollment through  days after the last dose of study treatment
Patients of childbearing potential must have negative pregnancy serum test within  hours of being dosed
Pregnant and/or breastfeeding; women of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least  mIU/mL within - days prior to and again within  hours of starting lenalidomide
Women of childbearing potential must have a negative serum pregnancy test within the -day period prior to randomization. (Where demanded by local regulations, this test may be required within  hours of randomization.)
Negative serum pregnancy test within  hours before starting study treatment in women with childbearing potential
Negative serum pregnancy test within  hours before starting study treatment in women with childbearing potential
Women of childbearing potential must have a negative serum pregnancy test during Screening Period and within  hours of the first dose of ARQ .
All necessary baseline studies for determining eligibility must be obtained within  days prior to enrollment. Serum pregnancy tests (sensitivity of at least  mIU/mL), for females of childbearing potential (WCBP) must be completed. The first test must be performed within - days, and the second test within  hours prior to initiation of lenalidomide.
For females of childbearing potential, a serum pregnancy test within  weeks prior to registration; note: if pelvic irradiation is to be given, the serum pregnancy test must be repeated within  hours prior to registration
Female subject of childbearing potential must have a negative serum pregnancy - days prior to registration, and again within  hours prior to the first dose of lenalidomide
For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than  mIU/m within  hours before the start of study medication
Subjects of reproductive potential must agree to the use of acceptable contraceptive methods for the duration of the time on study and a further  months after completion of treatment; women of childbearing potential must have a negative blood or urine pregnancy test within  hours of start of treatment
Negative serum pregnancy test within  hours before starting study treatment in women with childbearing potential
Female subjects of childbearing potential must have a negative serum pregnancy test at screening within  hours prior to the first study dose.
Women of childbearing potential must have a negative pregnancy test performed within  hours prior to the start of the study drug
Female patient of childbearing potential should have a negative urine or serum pregnancy test within  hours.
For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than  mIU/m within  hours before the start of study medication
Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within  to  days and again within  hours of starting study drug
Female patient has a negative serum pregnancy test within  hours prior to taking study drug if of childbearing potential, and agrees to abstain from activities that could result in pregnancy from enrollment through  days after the last dose of study treatment, or be of non-childbearing potential.
Women who are pregnant or nursing (pregnancy test to be performed within  hours prior to HIFU treatment)
Women who are pregnant or nursing (pregnancy test to be performed within  hours prior to HIFU treatment)
Negative serum or urine pregnancy test within  hours prior to registration for women of childbearing potential and agrees to use contraception for the duration of the treatment cycle and for a minimum of -days following the end of therapy (a minimum estimate  days)
Female participants of childbearing potential must have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study therapy
In women of child-bearing potential (WOCBP), a negative serum pregnancy test within  hours prior to procurement and again  hours prior to infusion is required
Positive serum or urine pregnancy test within  hours of imaging prior to injection of radiotracer (for women of childbearing potential per Radiology Department clinical guidelines)
Negative urine pregnancy test within  hours prior to study drug administration, if of childbearing potential
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within  hours prior to the restart of study drug
Female subject of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to dosing.
